These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Palliation of bone metastases: a survey of patterns of practice among Canadian radiation oncologists. Chow E; Danjoux C; Wong R; Szumacher E; Franssen E; Fung K; Finkelstein J; Andersson L; Connolly R Radiother Oncol; 2000 Sep; 56(3):305-14. PubMed ID: 10974379 [TBL] [Abstract][Full Text] [Related]
13. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529 [TBL] [Abstract][Full Text] [Related]
14. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373 [TBL] [Abstract][Full Text] [Related]
16. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Bolla M; Van Tienhoven G; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Billiet I; Torecilla JL; Pfeffer R; Cutajar CL; Van der Kwast T; Collette L Lancet Oncol; 2010 Nov; 11(11):1066-73. PubMed ID: 20933466 [TBL] [Abstract][Full Text] [Related]
17. Impact of elapsed treatment time on outcome of external-beam radiation therapy for localized carcinoma of the prostate. Perez CA; Michalski J; Mansur D; Lockett MA Cancer J; 2004; 10(6):349-56. PubMed ID: 15701266 [TBL] [Abstract][Full Text] [Related]
18. Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR). Kim YJ; Ahn H; Kim CS; Kim YS Radiat Oncol; 2020 Oct; 15(1):234. PubMed ID: 33032643 [TBL] [Abstract][Full Text] [Related]
19. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. Li XA; Wang JZ; Jursinic PA; Lawton CA; Wang D Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1251-7. PubMed ID: 15752907 [TBL] [Abstract][Full Text] [Related]
20. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Pollack A; Karrison TG; Balogh AG; Gomella LG; Low DA; Bruner DW; Wefel JS; Martin AG; Michalski JM; Angyalfi SJ; Lukka H; Faria SL; Rodrigues GB; Beauchemin MC; Lee RJ; Seaward SA; Allen AM; Monitto DC; Seiferheld W; Sartor O; Feng F; Sandler HM Lancet; 2022 May; 399(10338):1886-1901. PubMed ID: 35569466 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]